EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Efficacy of Recombinant Human Parathyroid Hormone 1–34 and Vitamin K2 Combination Therapy in Postmenopausal Osteoporosis

Zhuo Zhang, Kun Xia, Wentao Gong, Ruopeng Mai, Peng Liu, Zhaogang Lu

Hormone and Metabolic Research · 2025-01 · 57 (01) · 33-38

DOI: 10.1055/a-2371-1642 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Hormone and Metabolic Research, online erschienen am 28.08.2024. Verfasst von Zhuo Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Surgery of Spine and Bone Tumors, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, China. Hauptthemen laut MEDLINE: Osteoporosis, Postmenopausal, Vitamin K 2, Parathyroid Hormone. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Hospital training to revitalize research projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to assess the efficacy and safety of a combined recombinant human parathyroid hormone 1–34 [rhPTH (1–34)] and vitamin K2 therapy versus vitamin K2 alone in the treatment of postmenopausal osteoporosis. A total of 77 postmenopausal osteoporosis patients were randomly divided into two groups. Patients in one group received vitamin K2 alone, while patients in the other group received a combination of rhPTH (1–34) and vitamin K2. Bone mineral density (BMD), electrolyte levels, pain scores, bone metabolism levels, and adverse drug reactions were compared pre- and post-treatment. Both two treatments improved BMD, blood calcium concentrations, pain scores, and increased osteocalcin and osteoprotegerin levels. Notably, the combined rhPTH (1–34) and vitamin K2 treatment demonstrated superior efficacy in improving BMD and bone metabolism markers. Furthermore, there was no significant difference in the incidence of adverse reactions between the two groups, indicating the safety of the combined treatment. In summary, the combined therapy of rhPTH (1–34) and vitamin K2 exhibited more potent efficacy in the treatment of postmenopausal osteoporosis, more effectively enhancing BMD and bone metabolism markers than vitamin K2 alone, without a significant increase in adverse reactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Osteoporosis, PostmenopausalVitamin K 2Parathyroid HormoneHumansFemaleMiddle AgedBone DensityRecombinant ProteinsAgedDrug Therapy, CombinationCalciumOsteocalcin

Substanzen

Vitamin K 2Parathyroid HormoneRecombinant ProteinsCalciumOsteocalcin

Autor:innen und Institutionen

  • Surgery of Spine and Bone Tumors, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, China.
  • Department of Clinical Pharmacy, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, China.

Förderung

  • Hospital training to revitalize research projects

Zitieren

APA

Zhang, Z., Xia, K., Gong, W., Mai, R., Liu, P., & Lu, Z. (2025). Efficacy of Recombinant Human Parathyroid Hormone 1–34 and Vitamin K2 Combination Therapy in Postmenopausal Osteoporosis. Hormone and Metabolic Research, 57(01), 33-38. https://doi.org/10.1055/a-2371-1642

Vancouver

Zhang Z, Xia K, Gong W, Mai R, Liu P, Lu Z. Efficacy of Recombinant Human Parathyroid Hormone 1–34 and Vitamin K2 Combination Therapy in Postmenopausal Osteoporosis. Hormone and Metabolic Research. 2025;57(01):33-38. doi:10.1055/a-2371-1642

BibTeX
@article{Zhang2025,
  author = {Zhang, Zhuo and Xia, Kun and Gong, Wentao and Mai, Ruopeng and Liu, Peng and Lu, Zhaogang},
  title = {Efficacy of Recombinant Human Parathyroid Hormone 1–34 and Vitamin K2 Combination Therapy in Postmenopausal Osteoporosis},
  journal = {Hormone and Metabolic Research},
  year = {2025},
  volume = {57},
  number = {01},
  pages = {33--38},
  doi = {10.1055/a-2371-1642}
}
Kostenlos starten →